tetano
Editor, Senior Moderator
Influenza Other Respir Viruses
. 2025 Nov;19(11):e70191.
doi: 10.1111/irv.70191. COVID-19 Vaccine Effectiveness Against Hospitalization in Older Adults, VEBIS Hospital Network, Europe, September 2024-May 2025
Madelyn Rojas-Castro[SUP] 1 [/SUP], Nuno Verdasca[SUP] 2 [/SUP], Susana Monge[SUP] 3 [/SUP], Laurane De Mot[SUP] 4 [/SUP], Camino Trobajo-Sanmartín[SUP] 5 [/SUP], Róisín Duffy[SUP] 6 [/SUP], Gergő Túri[SUP] 7 [/SUP], Monika Kuliese[SUP] 8 [/SUP], Ralf Duerrwald[SUP] 9 [/SUP], Maria-Louise Borg[SUP] 10 [/SUP], Odette Popovici[SUP] 11 [/SUP], Verónica Gomez[SUP] 12 [/SUP], Zvjezdana Lovrić Makarić[SUP] 13 [/SUP], Odile Launay[SUP] 14 [/SUP], Diogo F P Marques[SUP] 1 [/SUP], Francisco Pozo[SUP] 15 [/SUP], Arne Witdouck[SUP] 16 [/SUP], Iván Martínez-Baz[SUP] 5 [/SUP], Margaret Fitzgerald[SUP] 6 [/SUP], Beatrix Oroszi[SUP] 7 [/SUP], Ligita Jančorienė[SUP] 17 [/SUP], Silke Buda[SUP] 9 [/SUP], Ausra Dziugyte[SUP] 10 [/SUP], Mihaela Lazăr[SUP] 18 [/SUP], Ausenda Machado[SUP] 12 [/SUP], Irena Tabain[SUP] 19 [/SUP], Liem Binh Luong Nguyen[SUP] 14 [/SUP], Eva Rivas Wagner[SUP] 20 [/SUP], François Dufrasne[SUP] 21 [/SUP], Jesús Castilla[SUP] 5 [/SUP], Lisa Domegan[SUP] 6 [/SUP], Viktória Velkey[SUP] 7 [/SUP], Fausta Majauskaite[SUP] 17 [/SUP], Carolin Hackmann[SUP] 22 [/SUP], Nathalie Nicolay[SUP] 23 [/SUP], Sabrina Bacci[SUP] 23 [/SUP], Angela M C Rose[SUP] 1 [/SUP]
Affiliations
We estimated COVID-19 vaccine effectiveness (VE) against PCR-confirmed SARS-CoV-2 hospitalization in patients ≥ 60 years with severe acute respiratory infection, using a multicenter, test-negative, case-control study across seven sites in six European countries between September 2024 and May 2025. We included 352 cases (115 vaccinated; 33%) and 9980 controls (5024 vaccinated; 50%). VE was 42% (95% CI: 15; 61) 14-59 days post-vaccination, 32% (95% CI: -1; 54) at 60-119 days, and 36% (95% CI: 2; 60) at 120-179 days, and no effect thereafter. Among adults aged 60-79 and ≥ 80 years, we observed moderate VE against COVID-19 hospitalization for up to 2 and 4 months, respectively.
Keywords: case–control study; elderly; severe acute respiratory infection (SARI); test‐negative design; vaccine effectiveness.
. 2025 Nov;19(11):e70191.
doi: 10.1111/irv.70191. COVID-19 Vaccine Effectiveness Against Hospitalization in Older Adults, VEBIS Hospital Network, Europe, September 2024-May 2025
Madelyn Rojas-Castro[SUP] 1 [/SUP], Nuno Verdasca[SUP] 2 [/SUP], Susana Monge[SUP] 3 [/SUP], Laurane De Mot[SUP] 4 [/SUP], Camino Trobajo-Sanmartín[SUP] 5 [/SUP], Róisín Duffy[SUP] 6 [/SUP], Gergő Túri[SUP] 7 [/SUP], Monika Kuliese[SUP] 8 [/SUP], Ralf Duerrwald[SUP] 9 [/SUP], Maria-Louise Borg[SUP] 10 [/SUP], Odette Popovici[SUP] 11 [/SUP], Verónica Gomez[SUP] 12 [/SUP], Zvjezdana Lovrić Makarić[SUP] 13 [/SUP], Odile Launay[SUP] 14 [/SUP], Diogo F P Marques[SUP] 1 [/SUP], Francisco Pozo[SUP] 15 [/SUP], Arne Witdouck[SUP] 16 [/SUP], Iván Martínez-Baz[SUP] 5 [/SUP], Margaret Fitzgerald[SUP] 6 [/SUP], Beatrix Oroszi[SUP] 7 [/SUP], Ligita Jančorienė[SUP] 17 [/SUP], Silke Buda[SUP] 9 [/SUP], Ausra Dziugyte[SUP] 10 [/SUP], Mihaela Lazăr[SUP] 18 [/SUP], Ausenda Machado[SUP] 12 [/SUP], Irena Tabain[SUP] 19 [/SUP], Liem Binh Luong Nguyen[SUP] 14 [/SUP], Eva Rivas Wagner[SUP] 20 [/SUP], François Dufrasne[SUP] 21 [/SUP], Jesús Castilla[SUP] 5 [/SUP], Lisa Domegan[SUP] 6 [/SUP], Viktória Velkey[SUP] 7 [/SUP], Fausta Majauskaite[SUP] 17 [/SUP], Carolin Hackmann[SUP] 22 [/SUP], Nathalie Nicolay[SUP] 23 [/SUP], Sabrina Bacci[SUP] 23 [/SUP], Angela M C Rose[SUP] 1 [/SUP]
Affiliations
- PMID: 41290396
- PMCID: PMC12646827
- DOI: 10.1111/irv.70191
We estimated COVID-19 vaccine effectiveness (VE) against PCR-confirmed SARS-CoV-2 hospitalization in patients ≥ 60 years with severe acute respiratory infection, using a multicenter, test-negative, case-control study across seven sites in six European countries between September 2024 and May 2025. We included 352 cases (115 vaccinated; 33%) and 9980 controls (5024 vaccinated; 50%). VE was 42% (95% CI: 15; 61) 14-59 days post-vaccination, 32% (95% CI: -1; 54) at 60-119 days, and 36% (95% CI: 2; 60) at 120-179 days, and no effect thereafter. Among adults aged 60-79 and ≥ 80 years, we observed moderate VE against COVID-19 hospitalization for up to 2 and 4 months, respectively.
Keywords: case–control study; elderly; severe acute respiratory infection (SARI); test‐negative design; vaccine effectiveness.